Apixaban (Eliquis) is likely cost-effective for atrial fibrillation (Afib) patients, despite the higher cost than generic warfarin, according to an economic analysis of the ARISTOTLE trial.
Trending:
NOAC 'Reasonably' Cost-Effective in Afib
Apixaban (Eliquis) is likely cost-effective for atrial fibrillation (Afib) patients, despite the higher cost than generic warfarin, according to an economic analysis of the ARISTOTLE trial.